Swiss pharmaceutical giant Novartis announced on Tuesday plans to eliminate up to 680 jobs within its development organization, a critical sector responsible for bringing its drugs to market.
The Basel-based company will see around 440 positions cut in Switzerland and up to 240 in the United States over the next two to three years. These job reductions are part of an initiative separate from a more significant restructuring effort, which Novartis previously indicated could affect up to 8,000 of its 78,000 global employees.
Despite these significant reductions, the company aims to reshape its capabilities and access local talent pools, particularly in data science and regulatory specializations, with a keen interest in the United Kingdom.